News

In the third quarter, the company saw 4 of its 6 highlighted assets approved, as well as approval for its quadrivalent flu vaccine, FluLaval. GSK also took a massive step forward this quarter as ...
It has also recently given tens of millions of dollars to the companies involved in making those vaccines—Sanofi, GSK, and CSL Seqirus—to ramp up their preparations to supply doses.
CSL Seqirus and GSK, under contract with HHS, are testing vaccines targeting a strain of avian influenza closely related to the one circulating in dairy cows. Each company is running trials in ...
Stefan Merlo, Vice President of Commercial Development at Seqirus, shares thoughts on the recent innovations in influenza vaccine technology.